BGP 15 is a calcipotriene-based vitamin D3 analog that inhibits poly(ADP-ribose) polymerasesis (PARP), a class of enzymes that regulate DNA repair and apoptosis (1). BGP 15 is also a cardioprotective agent (2). Also, BPG 15 improves mitochondrial function, protects neurons from dying in vitro and in vivo, and promotes cardiac innervation in vivo.
BGP-15 has been used to study its influence on proteasomal degradation of missense dystrophins.
BGP-15 is a hydroxylamine derivative, which has cytoprotective and neuroprotective properties. It reduces phospho- c-Jun N-terminal kinase (pJNK) and p38 stress signalling. BGP-15 also stimulates non-specific serine/threonine protein kinase (AKT) and insulin-like growth factor 1 receptor (IGFR1) protective signalling. BGP-15 functions as an insulin sensitizer in an olanzapine-induced metabolic disorder. It protects cells against cell death and enhances the expression of heat shock protein (HSP). BGP-15 might be used to treat heart failure (HF) and atrial fibrillation (AF).
BGP-15 is PARP inhibitor, HSP72 activator.
